Monthly Archives: November 2013

AbbVie largest program completed Phase III studies entirely oral, bezinterferonovogo regimen for hepatitis C genotype 1 .

99% SVR SVR12 in combination with ribavirin and without a number of categories of patients
Even in the most difficult to treat patient groups ( with cirrhosis ) achieved SVR12 at 92-96 %
AbbVie expects release of the drug to the U.S. market in 2014
hepatitis C

NORTH CHICAGO , Ill. , Jan. 31, 2014 – AbbVie (NYSE: ABBV) announced the completion of its Phase III clinical program and published the results of four additional studies examining completely oral , bezinterferonovuyu therapy in combination with ribavirin and without patients with chronic hepatitis C genotype 1 (GT1). The results described below confirm previously published data and company AbbVie continue to show a high incidence of sustained virologic response 12 weeks after the end of treatment (SVR12), and tolerability in patients with genotype 1 . Continue reading

Urethral stricture is called the restriction ( in some cases it may be a complete imperforate ) lumen of the urethra. From this definition, it becomes clear that urethral stricture prevents the normal emptying of the bladder. What is the consequence this state ?

Gradually increases in the bladder residual urine that eventually causes desensitization of the bladder and is reflected in its contractile ability . Because of this, there are problems with the kidneys, which can not function effectively and eventually develop kidney failure. Not cured stricture may also lead to the development of the following problems: Continue reading